Anargyros (Argiris) S.
- Country
- Greece
- Department
- Hematology Department
Research Overview
- Dose-Escalation and Dose-Finding Study of (S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)phenyl]-4-Methyl-4-Thiazolecarboxylic Acid in Transfusion-Dependent α- or β-Thalassemia
- Evaluation of Tumor Lysis Syndrome Risk in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax, Obinutuzumab, or Acalabrutinib Combinations
- Phase 3 Double-Blind Randomized Study of Lisaftoclax (APG-2575) and Azacitidine in Newly Diagnosed Higher-Risk Myelodysplastic Syndrome Patients
Data & Insights
Has run more than one trial at 73 of 179 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various blood cancers, with particular focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. Their expertise extends to evaluating novel therapeutic combinations for relapsed and refractory conditions.
- Multiple Myeloma Treatment Strategies
- Chronic Lymphocytic Leukemia Management
- Novel Drug Combinations
Lymphoid Disorders
Their clinical focus includes the treatment of Follicular Lymphoma, exploring innovative therapeutic approaches combining targeted therapies with established treatments. The investigator works with both treatment-naïve and previously treated patients.
- Follicular Lymphoma Therapies
- Immunotherapy Combinations
- Treatment Response Assessment
Bone Marrow Disorders
The investigator has extensive experience in treating Myelodysplastic Syndrome and Myeloproliferative Neoplasms. Their work includes addressing complications such as anemia and investigating novel therapeutic approaches for these conditions.
- Myelodysplastic Syndrome Management
- Myelofibrosis Treatment
- Anemia Management in Blood Disorders
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.